AMPK–SQSTM1 Feedback in Metabolic Stress

Study Background and Research Question

Metabolic stress in the tumor microenvironment is produced by nutrient depletion, altered glucose metabolism, mitochondrial dysfunction, and reactive oxygen species (ROS) accumulation. These pressures are closely linked: reduced nutrient flux can limit NADPH production, while oxidative damage can impair mitochondrial ATP generation and intensify energy stress. Cancer cells therefore require coordinated systems that preserve ATP, redox balance, and macromolecular quality control.

The STK11/LKB1–AMPK pathway is a central metabolic adaptation mechanism. Under energy stress, STK11 activates AMPK, which reduces energy consumption and promotes processes that sustain ATP and NADPH availability. A separate but complementary defense system is controlled by KEAP1 and NFE2L2/NRF2. When KEAP1-mediated degradation is weakened, NRF2 accumulates and induces antioxidant genes. The coexistence of STK11 and KEAP1 alterations in non-small cell lung cancer (NSCLC) raises an important biological question: how do cells compensate when one metabolic defense pathway is impaired while the NRF2 pathway is constitutively activated?

The reference study, Metabolic stress induces a double-positive feedback loop between AMPK and SQSTM1/p62 conferring dual activation of AMPK and NFE2L2/NRF2 to synergize antioxidant defense, addressed this question by examining SQSTM1/p62 as more than an autophagy adaptor. The authors asked whether metabolic stress-induced p62 expression and phosphorylation merely accompany AMPK activation, or whether AMPK and p62 form a reinforcing circuit that coordinates metabolic and antioxidant adaptation. The findings are reported in the reference study.

Key Innovation from the Reference Study

The principal innovation is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62. In the proposed model, metabolic stress increases p62, and p62 then drives two parallel outputs. First, p62 promotes autophagic degradation of KEAP1, releasing NFE2L2/NRF2 and strengthening antioxidant transcription. Second, p62 facilitates formation of an AXIN–STK11–AMPK complex at the lysosomal membrane, supporting AMPK activation. Thus, a single stress-responsive adaptor connects lysosomal signaling, energy sensing, autophagy, and redox defense.

The feedback is reciprocal. The study found that STK11–AMPK activity is required for the stress-induced increase in p62 expression and phosphorylation. This places AMPK downstream and upstream of p62 rather than treating the two pathways as independent branches. The resulting circuit can amplify both energy-stress signaling and NRF2-dependent antioxidant capacity, helping explain how metabolically challenged cancer cells maintain viability and growth.

A second important advance is the proposed mechanism controlling p62 abundance. Low-glucose metabolism and AMPK-dependent proton reduction were associated with lysosomal deacidification. This change promoted PPP2/PP2A-dependent dephosphorylation of TFEB and TFE3, transcription factors that regulate lysosome and autophagy-related gene programs. The authors therefore connect lysosomal pH to transcriptional induction of SQSTM1.

The study also places MAP3K7/TAK1 upstream of p62 phosphorylation. ROS and pH-dependent secretion of lysosomal calcium were associated with TAK1 activation, while p62 phosphorylation at S24 and S226 was reported to be important for activating both AMPK and NFE2L2/NRF2. This is a mechanistically useful distinction: p62 accumulation alone may not reproduce the full response if the relevant phosphosites and upstream stress signals are absent.

Methods and Experimental Design Insights

The experimental strategy combined metabolic-stress models with biochemical, genetic, and lysosome-focused perturbations. Low-nutrient or low-glucose conditions were used to reproduce the nutrient limitation relevant to tumor microenvironments. The investigators then monitored changes in p62 abundance and phosphorylation together with AMPK and NRF2 pathway activity. This design is important because it evaluates pathway coordination under stress rather than relying on constitutive pathway activation in unstressed cells.

Protein-level analyses were central to the study. Immunoblotting and related assays were used to follow AMPK activation, p62 expression, p62 phosphosites, KEAP1 abundance, and NRF2-associated responses. Immunoprecipitation-based experiments provided a way to test protein associations, including the AXIN–STK11–AMPK complex and interactions relevant to p62-dependent KEAP1 turnover. These measurements support a mechanistic sequence, although each proposed link still depends on the specificity of the perturbation used.

The authors also used lysosomal interventions to distinguish general nutrient stress from lysosome-specific effects. Bafilomycin A1 and concanamycin A appear in the study's experimental framework as tools for altering lysosomal acidification or V-ATPase-related function. Manipulation of lysosomal calcium signaling, ROS, and extracellular proton conditions further tested whether pH and calcium release were causal components of the pathway.

Genetic and pharmacological comparisons involving SQSTM1, STK11, KEAP1, AMPK, TFEB, and TFE3 helped position each component. The use of mouse embryonic fibroblasts alongside cancer-relevant models also improves mechanistic resolution by separating conserved stress biology from tumor-specific genotype effects. Importantly, the study examined rescue and interruption of the circuit rather than only measuring correlations between stress and p62.

Protocol Parameters

• Metabolic stress definition: Reproduce the study's low-nutrient or low-glucose logic, but record glucose, serum, cell density, and exposure duration explicitly because each can alter AMPK and lysosomal responses.
• Lysosomal controls: Use lysosome-acidification perturbations such as bafilomycin A1 or concanamycin A as mechanistic controls, not as interchangeable substitutes for nutrient withdrawal.
• Core readouts: Measure total and phosphorylated AMPK, SQSTM1/p62 abundance, p62 S24 and S226 phosphorylation, KEAP1 turnover, and NRF2 pathway activation in the same experiment.
• Causality tests: Pair loss-of-function or rescue experiments for SQSTM1, STK11, and AMPK with protein-interaction assays to distinguish pathway dependence from nonspecific stress toxicity.
• TAK1 follow-up: A pharmacological TAK1 perturbation should be combined with genetic confirmation and p62 phosphosite analysis. This is a follow-up workflow recommendation, not a parameter reported as proof of the paper's central model.

Core Findings and Why They Matter

The first major finding is that p62 is an active organizer of metabolic adaptation. Under metabolic stress, it simultaneously supports KEAP1 degradation and lysosomal AMPK activation. This dual function provides a plausible explanation for why cells with impaired STK11–AMPK signaling may gain particular advantage from KEAP1 loss or NRF2 activation: the two defense systems can compensate for one another while remaining connected through p62.

The second finding is that AMPK and p62 reinforce one another. AMPK is not simply a downstream sensor responding to falling energy availability. According to the published evidence, AMPK activity contributes to the transcriptional and post-translational induction of p62, while p62 is needed for robust activation of AMPK and NRF2. Such positive feedback may be especially valuable during prolonged stress, when a transient kinase response would otherwise decay.

The lysosomal mechanism adds another layer of significance. Lysosomes are presented as signaling platforms rather than passive degradative compartments. Reduced acidification, altered proton balance, and calcium release can influence TFEB/TFE3 activity, TAK1 activation, and assembly of the AXIN–STK11–AMPK complex. This model integrates nutrient sensing with organelle physiology and suggests that metabolic stress is interpreted through changes in lysosomal chemistry.

The role of TAK1 is particularly relevant for experimental dissection. ROS and lysosomal calcium-dependent signaling were linked to MAP3K7/TAK1 activation and p62 phosphorylation. Because p62 phosphorylation at S24 and S226 was important for downstream AMPK and NRF2 activation, TAK1 may function as a stress-sensitive gate that determines whether p62 is merely induced or becomes fully active. This does not establish that TAK1 inhibition will selectively eliminate tumor cells; rather, it identifies a testable control point in the feedback architecture.

Finally, the observation that lactic acid-derived protons abrogated the metabolic-stress response is biologically informative. It indicates that extracellular acid-base conditions can reshape the intracellular lysosomal signal. Tumor metabolism should therefore be modeled with attention to both nutrient availability and the chemical environment produced by neighboring cells.

Comparison with Existing Internal Articles

The internal article AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabolic Stress is closely aligned with this reference study and is useful as a concise conceptual companion. The present analysis places greater emphasis on the lysosomal pH, TFEB/TFE3, calcium, and TAK1 mechanisms that explain how the feedback loop is assembled.

A second relevant resource, TAK1 Inhibitor Workflows and Troubleshooting, addresses pharmacological interrogation of TAK1-linked signaling. Its workflow perspective can help design follow-up experiments around p62 phosphorylation, but it should not be treated as additional evidence that the reference authors used a particular TAK1 inhibitor or that pharmacological blockade reproduces every metabolic-stress phenotype.

Why this cross-domain matters, maturity, and limitations

The reference paper is centered on cancer-cell adaptation to metabolic and lysosomal stress, whereas TAK1 inhibitor workflows often focus on inflammatory signaling. The connection is mechanistically plausible because TAK1 is placed upstream of stress-induced p62 phosphorylation, but the bridge remains hypothesis-generating. Inflammation studies commonly emphasize NF-κB or JNK/p38 outputs, while this paper emphasizes AMPK, NRF2, lysosomal pH, and tumor survival. Direct transfer between these domains requires matched cell systems, orthogonal genetic controls, and measurements of the specific p62 phosphosites. It should not be assumed that an effect in an inflammation model predicts an effect on the AMPK–SQSTM1 circuit in STK11- or KEAP1-altered NSCLC.

Limitations and Transferability

Several limitations should guide interpretation. First, metabolic stress is experimentally defined and may not reproduce the fluctuating nutrient, oxygen, pH, and cytokine environment of a solid tumor. Second, positive feedback can create strong cell-state dependence: basal lysosomal function, STK11 status, KEAP1 status, and NRF2 activity may determine whether the circuit is protective or maladaptive.

Third, pharmacological tools that affect TAK1 or lysosomal function may produce pathway-wide effects that are not equivalent to selective alteration of p62 S24 or S226. Genetic rescue, phosphosite mutants, and time-resolved measurements are therefore important for causal attribution. Fourth, enhanced NRF2 and AMPK activity can protect normal cells as well as tumor cells, so therapeutic implications cannot be inferred from pathway activation alone.

Transferability to primary tumors, organoids, or animal models will require confirmation that the same lysosomal deacidification, calcium, TAK1, and p62-phosphorylation sequence occurs in vivo. The study provides a strong mechanistic framework, but it does not by itself establish a universal biomarker or treatment strategy for all lung cancers.

Research Support Resources

For follow-up mechanistic experiments, researchers can use (5Z)-7-Oxozeaenol (SKU B7443) as a selective TAK1 inhibitor to test whether TAK1-dependent signaling contributes to stress-induced p62 phosphorylation. Product information reports an approximately 8.1 nM IC50 against purified TAK1; this pharmacological probe should be paired with genetic controls and the AMPK, NRF2, KEAP1, and p62-phosphosite readouts described above. In separate inflammation-focused systems, it is also relevant as an inhibitor of NF-κB signaling, a JNK/p38 MAPK pathway inhibitor, a cyclooxygenase-2 (COX-2) production inhibitor, and an inflammation model compound. These applications support pathway comparison, but they do not replace direct validation of the AMPK–SQSTM1 mechanism in metabolic-stress models.